Maslimomab Biosimilar - Research Grade

Human

T cell receptor

>1mg/ml

IgG2b - nd

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the originator antibody maslimomab, built around the human T cell receptor (TCR) alpha/beta complex, and is intended strictly for research use only (not for human or veterinary use). The originator maslimomab is an immunosuppressive anti-TCR antibody directed at the alpha/beta chains of the T cell receptor; this research-grade analog reproduces that target specificity so investigators can use it as a defined, consistent reagent in laboratory settings. It is useful as a positive/isotype-comparison control, as a benchmarking tool alongside other anti-TCR reagents, for in-vitro binding and neutralisation experiments, and as a starting binder for ADC- or ADCC-format development work. It is supplied unconjugated so users can label or conjugate it as needed. The material is offered at research grade with low endotoxin (typically under 1 EU/mg, with ultra-low-endotoxin under 0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support scale-up, assay development, and preclinical characterisation. It is not the clinical drug. The T cell receptor (TCR) is a cell-surface antigen-recognition complex expressed on T lymphocytes. In most circulating T cells it consists of a disulfide-linked alpha and beta chain heterodimer, each with a variable and a constant domain, generated through V(D)J recombination to produce a highly diverse repertoire. The TCR recognises short peptide antigens presented by major histocompatibility complex (MHC) molecules on other cells. Because the alpha/beta heterodimer itself has short cytoplasmic tails and cannot signal alone, it associates non-covalently with the invariant CD3 chains (gamma, delta, epsilon) and the zeta homodimer, which carry the ITAM motifs that transduce activation signals. Engagement of the TCR-CD3 complex drives T cell activation, proliferation, and differentiation, making it central to adaptive immunity and a target of interest for immunomodulation and immuno-oncology research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Maslimomab (anti-T cell receptor) Biosimilar

Q: Is the Maslimomab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Maslimomab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Maslimomab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Maslimomab that binds T cell receptor; for research use only.